

ForPatients

by Roche

Skin Cancer Advanced Melanoma

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Trial Status Active, not recruiting	Trial Runs In 2 Countries	Trial Identifier NCT03815058 IMCODE001, 2018-001773-24 GO40558
---	-------------------------------------	---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Genentech, Inc. Sponsor	Phase 2 Phase
-----------------------------------	-------------------------

NCT03815058 IMCODE001, 2018-001773-24 GO40558
Trial Identifiers

Eligibility Criteria:

Gender All	Age >=18 Years	Healthy Volunteers No
----------------------	--------------------------	---------------------------------
